Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. McCleary-Wheeler AL, et al. Pancreatology. 2020 Jan;20(1):101-109. doi: 10.1016/j.pan.2019.11.011. Epub 2019 Nov 21. Pancreatology. 2020. PMID: 31787526 Free PMC article. Clinical Trial.
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. Moreno-Aspitia A, et al. Breast Cancer Res Treat. 2013 Apr;138(2):427-35. doi: 10.1007/s10549-013-2469-2. Epub 2013 Mar 12. Breast Cancer Res Treat. 2013. PMID: 23479422 Free PMC article. Clinical Trial.
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Weekes CD, et al. Mol Cancer Ther. 2016 Mar;15(3):439-47. doi: 10.1158/1535-7163.MCT-15-0693. Epub 2016 Jan 28. Mol Cancer Ther. 2016. PMID: 26823490 Clinical Trial.
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL. Norton N, et al. Breast Cancer Res. 2018 Jun 14;20(1):52. doi: 10.1186/s13058-018-0989-8. Breast Cancer Res. 2018. PMID: 29898752 Free PMC article. Clinical Trial.
CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.
McWilliams RR, Wieben ED, Chaffee KG, Antwi SO, Raskin L, Olopade OI, Li D, Highsmith WE Jr, Colon-Otero G, Khanna LG, Permuth JB, Olson JE, Frucht H, Genkinger J, Zheng W, Blot WJ, Wu L, Almada LL, Fernandez-Zapico ME, Sicotte H, Pedersen KS, Petersen GM. McWilliams RR, et al. Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1364-1370. doi: 10.1158/1055-9965.EPI-17-1065. Epub 2018 Jul 23. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 30038052 Free PMC article.
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
Colon-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Wahner Hendrickson A, Jatoi A, Block MS, Langstraat CL, Glaser GE, Dinh TA, Robertson MW, Camoriano JK, Butler KA, Copland JA, Weroha SJ. Colon-Otero G, et al. ESMO Open. 2020 Oct;5(5):e000926. doi: 10.1136/esmoopen-2020-000926. ESMO Open. 2020. PMID: 33109627 Free PMC article. Clinical Trial.
87 results